Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers

NCT01292070 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT01292070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01292070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2011
Completion date
April 30, 2011
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cat allergy